To assess the magnitude and duration of the antiviral activity in plasma and the incidence
and time to total suppression of detectable HIV RNA in plasma. To assess the long-term
safety and tolerability of this combination therapy and the magnitude and duration of the
effect of this therapy over CD4 cell counts.
Patients must have:
- Documented HIV infection.
- CD4 count > 500 cells/mm3.
- No HIV-associated symptoms.
- Written, informed consent from parent or legal guardian for patients < 18 years old.
- Availability for follow-up for at least 96 weeks.
Patients with the following conditions and symptoms are excluded:
- Presence of a newly diagnosed AIDS-defining opportunistic infection requiring acute
therapy at the time of enrollment.
- Intractable diarrhea.
- Signs and symptoms of bilateral peripheral neuropathy >= Grade 2.
- Inability to tolerate oral medication.
- Hemophilia, other bleeding disorder, or no accessible tonsillar or lymph node tissue.
Patients with the following prior conditions are excluded:
History of acute or chronic pancreatitis. 1. Use of potent neurotoxic drugs is not
- No other anti-HIV therapy allowed.
- Nelfinavir should not be administered concurrently with rifampin or rifabutin,
terfenadine (Seldane), astemizole (Hismanal), cisapride (Propulsid), triazolam
(Halcion), and midazolam (Versed).
1. Any prior antiretroviral therapy.
- Prior vaccination with a candidate HIV therapeutic vaccine.
- Previous therapy with agents with significant systemic myelosuppressive, neurotoxic,
pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of study start or
the expected need for such therapy at the time of enrollment.
- Previous therapy with rifampin or rifabutin, terfenadine (Seldane), astemizole
(Hismanal), cisapride (Propulsid), triazolam (Halcion), and midazolam (Versed) within
14 days prior to study entry or at any time while on study.
Active alcohol or substance abuse.